OR WAIT null SECS
September 16, 2024
It’s essential for commercial success, but presents its share of obstacles.
September 10, 2024
A pooled analysis of the SWIFT-1 and SWIFT-2 trials found 54% reduction in exacerbation rates over 52 weeks in patients with severe asthma with type 2 inflammation treated with depemokimab.
September 05, 2024
This year’s conference—taking place in Washington, DC— will prioritize the tackling of business, economic, and healthcare policy obstacles when it comes to decision marking and net revenue optimization.
August 06, 2024
ROCTAVIAN will only be sold to the United States, Italian, and German markets, as the company eyes its profitability by 2025.
July 25, 2024
The parties will continue to create new candidate therapies for the treatment of a severe form of TUBB4A leukodystrophy.
July 08, 2024
Expansion of these offerings will occur at the company’s 60,000 square-foot Lincolnshire Center of Excellence
June 06, 2024
Ashfield Event Experiences and WRG merge in an effort to better serve the healthcare industry.
June 03, 2024
In an interview with Pharma Commerce Editor Nicholas Saraceno, Lung-I Cheng, PhD, VP, Head of Cell & Gene Therapy Service Line, Cencora offers his thoughts on Cencora's inaugural ThinkLive Cell and Gene Therapy Summit.
March 15, 2024
Biosimilars market experiences massive growth, but regulatory and adoption challenges remain.
March 07, 2024
The CDMO’s multi-million-dollar expansion project features commercial manufacturing suites and peptide manufacturing plants.